Profile
| Metric | Value |
|---|---|
| Full Name | Intellia Therapeutics, Inc. |
| Ticker | NASDAQ: NTLA |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | intelliatx.com |
| Employees | 403 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $11.43 | |
| Price, 1D Change | +10.17% | |
| Market Cap | $1B | |
| - | ||
| PE Ratio | - | |
| Beta | 1.46 | |
| Revenue | $58M | |
| Revenue, 1Y Change | +59.55% | |
| EPS | -$5.25 | |
| EPS, 1Y Change | +3.14% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$5.25 | |
| EPS Estimate | -$4.00 | |
| EPS Est. Change | +23.79% | |
| Revenue | $57.88M | |
| Revenue Estimate | $57.09M | |
| Revenue Est. Change | -1.36% | |
| Current Price | $11.43 | |
| Price Target | - | $14.00 |
| Price Tgt. Change | - | +22.48% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$5.40 | -$5.42 | -0.38% | |
| -$5.27 | -$5.25 | +0.43% | |
| -$4.00 | N/A | +23.79% | |
| -$3.59 | N/A | +31.55% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $51.55M | $36.28M | -29.63% | |
| $52.11M | $57.88M | +11.08% | |
| $57.09M | N/A | -1.36% | |
| $51.39M | N/A | -11.21% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +12.06% | |
| Price, 3Y | -70.09% | |
| Market Cap, 1Y | +27.22% | |
| Market Cap, 3Y | -60.22% | |
| Revenue, 1Y | +59.55% | |
| Revenue, 3Y | +75.10% | |
| EPS, 1Y | +3.14% | |
| EPS, 3Y | -38.95% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $11.43 | |
| SMA 200 | $11.36 | |
| SMA 200 vs Price | -0.58% | |
| SMA 50 | $9.62 | |
| SMA 50 vs Price | -15.83% | |
| Beta | 1.46 | |
| ATR | $0.68 | |
| 14-Day RSI | 66.31 | |
| 10-Day Volatility | 60.91% | |
| 1-Year Volatility | 100.76% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $57.88M | |
| EPS | -$5.25 | |
| Gross Profit | $47.59M | |
| Gross Margin | 82.23% | |
| Operating Profit | -$534.26M | |
| Operating Margin | -923.10% | |
| Net Income | -$519.02M | |
| Net Margin | -896.77% | |
| EBITDA | -$523.98M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.24 | |
| Current Ratio | 5.77 | |
| Quick Ratio | 5.77 | |
| - | ||
| F-Score | 3 | |
| Altman Z-Score | -0.97 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| PS Ratio | 23.01 | |
| PB Ratio | 1.77 | |
| EV/EBITDA | -1.98 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $871.96M | |
| Cash & Equivalents | $189.18M | |
| Total Assets | $1.19B | |
| Current Assets | $639.86M | |
| Total Liabilities | $319.06M | |
| Current Liabilities | $110.85M | |
| Total Debt | $210.20M | |
| Short Term Debt | $20.25M | |
| Accounts Payable | $14.59M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $576.90M | |
| Operating Expenses | $581.86M | |
| Cost Of Goods Sold | $10.29M | |
| SG&A | $0.00 | |
| D&A | $10.29M | |
| Interest Expense | $0.00 | |
| Income Tax | $0.00 |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | -$348.88M | |
| CFI | $125.57M | |
| CFF | $185.75M | |
| Capex | $5.78M | |
| Free Cash Flow | -$354.66M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Wolfe Research | → | |
| Jones Trading | → | |
| Evercore ISI Group | → | |
| Truist Securities | → | |
| HC Wainwright & Co. | → | |
| Wells Fargo | → | |
| Wedbush | → | |
| RBC Capital | → | |
| JP Morgan | → | |
| Citizens | → |
Analyst sentiment
Institutional ownership
Screeners with NTLA
Data Sources & References
- NTLA Official Website www.intelliatx.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1652130/000119312525269680/0001193125-25-269680-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1652130/000095017025029007/0000950170-25-029007-index.htm
- NTLA Profile on Yahoo Finance finance.yahoo.com/quote/NTLA
- NTLA Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/ntla
FAQ
What is the ticker symbol for Intellia Therapeutics, Inc.?
The ticker symbol for Intellia Therapeutics, Inc. is NASDAQ:NTLA
Does Intellia Therapeutics, Inc. pay dividends?
No, Intellia Therapeutics, Inc. does not pay dividends
What sector is Intellia Therapeutics, Inc. in?
Intellia Therapeutics, Inc. is in the Healthcare sector
What industry is Intellia Therapeutics, Inc. in?
Intellia Therapeutics, Inc. is in the Biotechnology industry
What country is Intellia Therapeutics, Inc. based in?
Intellia Therapeutics, Inc. is headquartered in United States
When did Intellia Therapeutics, Inc. go public?
Intellia Therapeutics, Inc. initial public offering (IPO) was on May 6, 2016
Is Intellia Therapeutics, Inc. in the S&P 500?
No, Intellia Therapeutics, Inc. is not included in the S&P 500 index
Is Intellia Therapeutics, Inc. in the NASDAQ 100?
No, Intellia Therapeutics, Inc. is not included in the NASDAQ 100 index
Is Intellia Therapeutics, Inc. in the Dow Jones?
No, Intellia Therapeutics, Inc. is not included in the Dow Jones index
When was Intellia Therapeutics, Inc. last earnings report?
Intellia Therapeutics, Inc.'s most recent earnings report was on November 6, 2025
When does Intellia Therapeutics, Inc. report earnings?
The next expected earnings date for Intellia Therapeutics, Inc. is February 26, 2026